Irinotecan liposomes for pancreatic or gastrointestinal neuroendocrine cancer
Part of Cancer clinical trials.
This trial tests whether a liposomal form of the chemotherapy drug irinotecan can help people with advanced neuroendocrine tumors or cancers of the pancreas or gastrointestinal tract. It is designed for those who have not had prior systemic treatment or who have not received it yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a high-grade neuroendocrine tumor (G3) or neuroendocrine carcinoma in the pancreas or digestive tract, confirmed by biopsy.
- You have not had previous treatment for this cancer, or you have but it was not systemic (like localized therapy only).
- You have at least one tumor that is measurable on a CT scan (at least 1 cm in the longest diameter).
- Your overall health is good enough to perform daily activities (ECOG score of 0-2).
- Your blood counts and liver/kidney function meet specified minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) for people with advanced, aggressive neuroendocrine cancer that has not responded to at least one prior treatment. The goal is to see if this version of the drug works better or has fewer side effects.
This trial tests a new liposomal form of irinotecan in combination with other drugs as a second or later treatment for people with advanced pancreatic cancer that continued to grow after prior irinotecan therapy. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests adding a new immunotherapy drug (addebelizumab) to standard chemotherapy for people with pancreatic cancer that can be removed by surgery. The goal is to see if the combination shrinks tumors more effectively before surgery.
This trial tests a new combination therapy using liposomal irinotecan for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line treatment. It may be an option if you are looking for a second-line therapy.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.